Searched for
DASH PHARMACEUTICALS
Saving supply chains from climate shocks is a lure for investorsCompanies are increasingly focused on supply chain resilience. This trend is expected to continue, offering new opportunities and protectin...- Shivinder Mohan Singh moves NCLT, files plea for personal insolvencyShivinder Mohan Singh, the former Fortis Healthcare promoter, has sought personal insolvency before the NCLT, citing liabilities exceeding ...
- Complaint filed against Natco Pharma in US by Fresenius KabiNatco Pharma faces a legal complaint from Fresenius Kabi in the US District Court regarding the marketing of Diazepam injection prefilled s...
- Pakistan hospitals facing shortage of crucial drugs like insulin, doctors postponing surgeriesAs per Pakistan media reports, the operation theatres are left with less than the two-week stock of anaesthetics needed for sensitive surge...
- Stocks in the news: Tata Motors, NTPC, Greaves Cotton, NMDC and autosThe hiving off and transfer of Tata Group auto arm's entire passenger vehicle undertaking to Tata Motors Passenger Vehicles Ltd have come i...
- Stocks in the news: ITC, Vedanta, SBI, Emami, HDFC and NatcoMulti-business conglomerate ITC has not given any concrete plan for demerger and listing of businesses to unlock value at its analyst meet.
- Natco Pharma proposes to acquire Dash PharmaceuticalsAccording to a press release issued by the Hyderabad-based drug maker, Dash is a front-end pharmaceutical sales, marketing and distribution...
- Investors seeking safe-haven plays"Hospitality stocks can be the worst hit if lockdowns are implemented in various countries and travel from affected countries like South Af...
- Glenmark Pharma to study potential Covid-19 drug combinationThe study will look to enroll 158 hospitalized patients of moderate Covid-19 in India, the company added. Last month, Glenmark said it woul...
- Sebi asks 10 entities to make open offer to Mindvision Capital's shareholdersThe entities have been asked to make the open offer within 45 days from April 15.
- ET 40 Under Forty: When corporate big bosses looked sharper than their suitsThe entrepreneurial stars brought to the power room an interesting mix of classic staples and bold accessories.
- Pharma sector seeing a relief rally: Dipan Mehta, BSE & NSE“Never have US presidential elections made a material difference to the trends in our market or our economy. It is just that it is an impor...
- Delhi HC Upholds BMS' Patent for Cancer Drug DasatinibThe Delhi High Court has upheld the patent of US-based BMS for Dasatinib, dashing the hopes of a local company to sell a generic version of...
- Delhi High Court upholds BMS’ patent for cancer drug DasatinibThe Indian Patent Office had in 2013 rejected the company’s demand for a compulsory licence as it did not follow the procedures for obtaini...
- Follow up meeting on 'Make in India' campaign on December 29During the day long workshop, which would be organised by the Commerce and Industry Ministry, senior industry leaders would also participat...
- Gems & jewellery, SME, 3 others to come under 'Make in India'The govt has identified 25 sectors, including pharma, auto, textiles, aviation, mining, chemicals, which have potential to make India a lea...
- Tainted company Seashore Group top bidder for handling Odisha doleSeashore Group, accused of cheating depositors of Rs 300-400 cr, puts in bid of -0.06% to become banking correspondent for Odisha.
- Foreign Investment Promotion Board defers pharmaceuticals sector FDI proposalsThe approval authority deferred all foreign investment proposals in the pharma, dashing foreign firms' hopes that their applications may fi...
- Volatile market takes toll on Pharmaceuticals and healthcare IPO plansThe market has hit the IPO plans of pharma and healthcare companies with several firms either withdrawing or deferring their offers.
- GlaxoSmithKline to slash costs, jobs as profits dropBritish pharmaceutical giant GlaxoSmithKline said on Wednesday it would cut jobs and costs as it blamed a fall in third-quarter profits on ...
Load More
